InMed Pharmaceuticals Inc.
For the period ended Mar 9, 2026. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 9, 2026 · Filed Mar 9, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Scientific and development progress and plans include:
Scientific and development progress and plans include:
Generation of data supporting continued evaluation of therapeutic potential.
Completion of preclinical studies, including dose-ranging assessment, demonstrating dose proportionality and pharmacologically relevant concentration following dosing.
Drug substance and drug product process in place to support IND enabling studies, with further optimization expected in advance of IND submission.
Planning for a pre-IND meeting with the FDA in Q4 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.